



Patient Care + Research + Clinical Trials

**Dr. Tom Elliott MBBS, FRCPC**  
**Medical Director**

400 - 210 W Broadway  
Vancouver, BC  
V5Y 3W2 Canada email:

phone: 604.683.3734  
fax: 604.628.3821  
moa@bcdiabetes.ca

## Semaglutide for weight loss and diabetes control

Semaglutide, originally branded as Ozempic, now also branded as [Wegovy](#) and with numerous generic versions including [apo-semaglutide](#), is the most widely used GLP-1 agonist on the Canadian market. Three months use of the on average is associated with 5% weight loss and reduction in A1c of 0.8%. It is also effective for weight loss in the absence of diabetes.

For tips on food choices for best results and to minimize side-effects, [click here](#).

Other GLP-1 agonists on the Canadian market include highly potent [tirzepatide](#) branded as Mounjaro and Zepbound, and less potent dulaglutide “Trulicity” and daily injectables liraglutide “Victoza”.

Semaglutide is most commonly given by an injection once a week - [see this how-to youtube video demo](#). Semaglutide is also available as a daily tablet “Rybelsus” in formulations of 3, 7 and 14 mg. Doses of oral semaglutide 25 mg daily (a US study) gave approximately the same results of 2.4 mg of injectable semaglutide given weekly.

Semaglutide’s only significant side-effect is nausea which is usually mild and settles with time, particularly if the dose is started low and increased slowly. **The usual starting dose for semaglutide is 0.25 mg weekly (18 clicks on the pen). If after 4 weeks nausea is minimal the dose should be increased to 0.5 mg (36 clicks) and this dose continued for another 4 weeks. If target weight or sugar has not been achieved and nausea is absent or minimal, the dose is increased to 1.0 mg weekly (72 clicks), the usual maintenance dose.** If a dose of 1.0 mg weekly for at least one month or more does not result in the desired sugar value or if further weight loss is desired, higher doses of semaglutide can be considered. Note, doses of semaglutide > 1.0 mg weekly are not approved by Health Canada, and any higher dose is considered “off-label” and requires a physician’s express signature. Typical doses are then 1.7 mg weekly (126 clicks) for a month then 2.4 mg weekly (172 clicks) indefinitely. The same 2.4 mg per week semaglutide dose is approved for weight loss in the United States under the trade name “Wegovy”. Wegovy is available in pens intended for single dose containing 0.25, 0.5, 1.0, 1.7 and 2.4 mg per pen.

In February 2026 the United Kingdom, [a dose of Ozempic of 7.2 mg weekly](#) was approved for weight loss. Higher doses have greater effects - check these links for [weight loss](#) & [lowering of A1c](#) as the dose of semaglutide is increased from 0.5 mg weekly to 7.2 mg weekly.

If persistent nausea or vomiting occurs with semaglutide, the dose should be held until the nausea disappears and then potentially reintroduced at no more than 50% of the previous dose. Some clinics employ in-between or micro doses of semaglutide measured in clicks, not milligrams. The Ozempic brand of semaglutide 4 mg pen requires 72 clicks for 1 mg. The apo-semaglutide brand of 4 mg pen requires 75 clicks for 1 mg. Using the Ozempic brand, if a client tolerates 0.25 mg per week (18 clicks) but not 0.5 mg per week (36 clicks), an in-between dose of 0.375 mg (27 clicks weekly) could be tried. For those who do not tolerate 0.25 mg weekly (18 clicks, the usual starting dose) they might try 0.125 mg (9 clicks) weekly or even smaller doses.

Despite media claims that semaglutide can cause a form of “stomach paralysis”, Dr. Elliott is of the opinion that this is not the case - [see his 2023-Aug-08 on this subject on the CTV morning show by host Kerri Adams](#).

If semaglutide is stopped for more than two weeks and planned for reintroduction it should be restarted at the usual starting dose of 0.25 mg weekly, not the previously tolerated dose.

Semaglutide comes in two pen sizes: 2 mg (sample size and usual starting size with prescriptions designed for 4 weekly shots of 0.5 mg) and 4 mg pens (designed for 4 weekly shots of 1 mg). Both the 2 mg and 4 mg pens cost the same - \$78 at Costco. For clients on long-term semaglutide, it is 50% cheaper if their doctor prescribes the 4 mg pen. The doctor should be asked to add to the prescription “dispense 4 mg pens”. At 1 mg weekly the cost is \$2.40 per day.

Does semaglutide reduce dementia? This is a question that many researchers are asking. Pre-clinical evidence suggests that drugs in the GLP-1 class, including tirzepatide, may do so - for a review article on this subject [click here](#). BCDiabetes is working on a collaboration with the author Simon Cork in the UK.

Short URL = <https://bit.ly/BCDsemaglutide>